Lenstec, Inc. (St. Petersburg, FL) is proud to announce today, that the first U.S. commercial implantations of their newly FDA approved SBL-3 ClearViewTM Multifocal Intraocular lens (MIOL) were performed by Jeff Whitsett, MD of Whitsett Vision (Houston, TX).
The SBL-3 Clearview Multifocal is a next generation presbyopia correcting IOL design, that in FDA clinical trials provided patients with near, intermediate and distance vision, with reports of much lower visual disturbances than traditional MIOLs. Additionally, over 90% of patients achieved binocular visual acuities of 20/25 or better at all distances, as well as over 93% reporting spectacle independence.
Dr. Whitsett served as a principal investigator in FDA trials of the ClearView MIOL. He notes, “Patients have reported high levels of satisfaction with minimal side effects. I believe the SBL-3 ClearView MIOL will be an excellent option for refractive lens surgeons.”
"Lenstec is proud to have a surgeon of Dr Whitsett's caliber be the first to implant our new ClearView MIOL in the US," says Jimmy Chacko, Vice President of Regulatory Affairs at Lenstec. "Years of clinical trial work by him and his staff helped catapult Lenstec into the presbyopia correction arena. We look forward to his continued use and exceptional outcomes for his patients"
About Whitsett Vision Group
Jeffrey Whitsett, MD founded Whitsett Vision Group in 1999, with a goal of bringing superior eye care and surgical vision treatment options to the city of Houston. Dr. Whitsett specializes in custom cataract surgery and custom LASIK, focusing on providing patients with the best visual outcomes after surgery. He has had incredible success in helping patients become glasses-free after surgery.
About Lenstec
Lenstec is a leading designer and manufacturer of intraocular Lenses (IOLs) to treat patients with a range of vision disorders. Founded in 1992, the company is dedicated to advancing possibilities for ophthalmic professionals and their patients worldwide.
The SBL-3 Clearview Multifocal is a next generation presbyopia correcting IOL design, that in FDA clinical trials provided patients with near, intermediate and distance vision, with reports of much lower visual disturbances than traditional MIOLs. Additionally, over 90% of patients achieved binocular visual acuities of 20/25 or better at all distances, as well as over 93% reporting spectacle independence.
Dr. Whitsett served as a principal investigator in FDA trials of the ClearView MIOL. He notes, “Patients have reported high levels of satisfaction with minimal side effects. I believe the SBL-3 ClearView MIOL will be an excellent option for refractive lens surgeons.”
"Lenstec is proud to have a surgeon of Dr Whitsett's caliber be the first to implant our new ClearView MIOL in the US," says Jimmy Chacko, Vice President of Regulatory Affairs at Lenstec. "Years of clinical trial work by him and his staff helped catapult Lenstec into the presbyopia correction arena. We look forward to his continued use and exceptional outcomes for his patients"
About Whitsett Vision Group
Jeffrey Whitsett, MD founded Whitsett Vision Group in 1999, with a goal of bringing superior eye care and surgical vision treatment options to the city of Houston. Dr. Whitsett specializes in custom cataract surgery and custom LASIK, focusing on providing patients with the best visual outcomes after surgery. He has had incredible success in helping patients become glasses-free after surgery.
About Lenstec
Lenstec is a leading designer and manufacturer of intraocular Lenses (IOLs) to treat patients with a range of vision disorders. Founded in 1992, the company is dedicated to advancing possibilities for ophthalmic professionals and their patients worldwide.
RSS Feed